All

Liquid Biopsy Launched at Florida Cancer Institute

Florida Cancer Specialists & Research Institute now offers liquid biopsy, a minimally invasive blood test that enhances cancer diagnosis.

All

NCCN Guidelines Add ctDNA-MRD Testing Recommendation for B-Cell Lymphoma

Foresight Diagnostics’ ctDNA-MRD testing has been included in the NCCN Clinical Practice Guidelines for diffuse large B-cell lymphoma.

All

Why ESR1 Mutation Monitoring Can Keep One Step Ahead of Breast Cancer

For patients with metastatic HR+ breast cancer, there may be no test more important than monitoring for an ESR1 mutation.

Personalis’ MRD Assay Detects ctDNA in Lung Cancer Patients Earlier

Oct 23, 2023 | Lung Cancer, Molecular Diagnostics

NeXT Personal ctDNA assay shown to be more sensitive and predictive of clinical outcomes in early-stage lung cancer patients

AMP Publishes Best Practice Recommendations for Liquid Biopsy Assay Validation

Oct 12, 2023 | Molecular Diagnostics

The AMP published a set of best practice recommendations for validating and reporting clinical ctDNA or liquid biopsy assays.

Blood Tests Identify NSCLC Patients Who May Benefit from Immunotherapies

Oct 9, 2023 | Lung Cancer

Liquid biopsies may identify NSCLC patients undergoing immunotherapy who could benefit from treatment with additional drugs.

Personalis & BC Cancer Assess Benefits of ctDNA for Colorectal, Pancreatic Cancers

Aug 15, 2022 | Colorectal, Pancreatic

Personalis and BC Cancer will deploy a personalized liquid biopsy-based assay for a study of patients with colorectal and pancreatic cancers.

Twist Bioscience’s New Customizable Panels to Advance Minimal Residual Disease Detection

Jun 8, 2022 | Cancer

Twist Bioscience launched a custom solution for NGS workflow, offering fully customizable panels to quickly detect minimal residual disease.

Predicine Liquid Biopsy Outperforms in ctDNA Assay Study

May 13, 2022 | Cancer, Molecular Diagnostics

A new research study showed the PredicineATLAS liquid biopsy next-generation sequencing assay outperforming four other leading assays.

Foundation Medicine’s ctDNA Monitoring Assay Granted FDA Breakthrough Device Designation

Feb 16, 2022 | Cancer

The assay uses algorithms for identifying patient-specific variants and a personalized assay design that allows for the detection of ctDNA in plasma.

Twist Bioscience Launches cfDNA Reference Controls

Dec 24, 2021 | Cancer, Controls

Twist Bioscience Corporation has launched the Twist cfDNA Pan-cancer Reference Standards for use liquid biopsy tests to detect cancer from blood samples.

Foresight Diagnostics’ ctDNA Liquid Biopsy Platform Streamlines Treatment of B-Cell Lymphoma

Dec 22, 2021 | Immunoassay, Lymphoma

Detection of ctDNA levels with the assay was correlated with detected changes in tumor burden in B-cell lymphoma patients treated with acalabrutinib.

Why Testing ROI & Patient Access Aren’t Mutually Exclusive

Dec 20, 2021 | Sequencing Systems

Genapsys CEO Jason Myers explains how his company is planning to solve return on investment and patient access with the company’s NGS platform.

Invitae Opens Early Access to Liquid Biopsy-Based Personalized Cancer Monitoring Test

Jun 7, 2021 | Cancer

Full commercial availability of the Invitae liquid biopsy-based PCM as a laboratory-developed test is expected later this year.

Advances in Liquid Biopsy

Mar 3, 2021 | Cancer, Molecular Diagnostics

Developing technology ushers in a new era in precision oncology.

nRichDX Launches Revolution Sample Prep Semi-Automated Workflow

Jan 29, 2021 | Lab Automation

The new semi-automated workflow is designed to increase yield, sensitivity, and throughput by delivering exponentially more target cfDNA and ctDNA for molecular assays with greater automation and reduced hands-on technician time.